AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the ...

Shares of AbbVie Inc. ABBV slipped 0.74% to $174.37 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6,084.19 and ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

The stock's fall snapped a two-day winning streak.

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...